# A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy

> **NCT04159493** · PHASE2 · WITHDRAWN · sponsor: **Aspen USA Inc**

## Conditions studied

- Vaginal Atrophy

## Interventions

- **DRUG:** Estriol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04159493
- **Lead sponsor:** Aspen USA Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-05
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-05-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Project terminated IND withdrawn
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159493, "A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04159493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*